Reata Pharmaceuticals Inc. Cl A | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$3.99 |
Market Cap |
$2.7 B |
Shares Outstanding |
24.42 M |
Public Float |
22.32 M |
Address |
2801 Gateway Drive Irving Texas 75063 United States |
Employees | - |
Website | http://www.reatapharma.com |
Updated | 07/08/2019 |
Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its lead product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. |